Sagimet Biosciences Inc. (SGMT) Cash Flow Statement
Sagimet Biosciences Inc. (SGMT) generated -$41.7M of operating cash flow over the twelve months to 2026-06-30, spent $0 on capital expenditure and had free cash flow of -$41.7M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
SGMTSagimet Biosciences Inc.Follow SGMT — free
—
Price chart with a free account
- Market cap
- 595.5M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 12 Nov, in 19 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Operating cash flow | -23.8 | -42.4 | -45.7 | -41.7 | |
| Capital expenditure | — | 0.0 | 0.0 | -0.0 | |
| Free cash flow | — | -42.4 | -45.7 | -41.7 | |
| Stock-based compensation | 5.0 | 5.3 | 6.4 | — |
USD millions · SEC XBRL
Sagimet Biosciences Inc. — questions
- What is Sagimet Biosciences Inc.'s operating cash flow?
- -$41.7M over the twelve months to 2026-06-30.
- How much does Sagimet Biosciences Inc. spend on capital expenditure?
- $0 over the twelve months to 2026-06-30.
- What is Sagimet Biosciences Inc.'s free cash flow?
- -$41.7M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Sagimet Biosciences Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.